Ignite Creation Date:
2025-12-24 @ 11:38 PM
Ignite Modification Date:
2026-01-01 @ 1:39 AM
Study NCT ID:
NCT04777851
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-15
First Post:
2021-02-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
Sponsor:
Translational Research in Oncology
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-10-11
Start Date Type:
ACTUAL
Primary Completion Date:
2026-02-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-02-28
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-25
First Submit QC Date:
None
Study First Post Date:
2021-03-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-14
Last Update Post Date:
2025-05-15
Last Update Post Date Type:
ACTUAL